Literature DB >> 26332755

Clinical Expression of Calcium Sensing Receptor Polymorphism (A986S) in Normocalcemic and Asymptomatic Hyperparathyroidism.

G Díaz-Soto1, E Romero1, J L P Castrillón2, O I Jauregui1, D de Luis Román1.   

Abstract

Normocalcemic and asymptomatic hyperparathyroidism diagnosis are becoming more common. However, their pathophysiology is incompletely known. The aim of the present study was to evaluate the clinical effect of calcium-sensing receptor polymorphism (A986S) in normocalcemic and asymtomatic HPT. Prospective study conducted with 61 consecutive normocalcemic and asymptomatic HPT patients was followed up during a minimum period of 1 year. Secondary causes of hyperparathyroidism were ruled out. Calcium and phosphorus metabolism parameters were evaluated in at least 2 determinations during follow-up to classify as normocalcemic or asymptomatic hyperparathyroidism. Bone mineral density and A986S polymorphism genotype were also analyzed. Thiry-eight patients (62.3%) had the genotype A986A, and 23 (36.7%) patients had A986S (20 patients, 32.8%) or S986S (3 patients, 4.9%). Age, sex, and genotype distributions were comparable in both normocalcemic and asymptomatic hyperparathyroidism. In normocalcemic patients, S allele genotype was associated to statistically significant higher level of intact PTH: 92.0 (SD 18.5) vs. 110.6 (SD 24.4) pg/ml, p<0.05; and remained significant after adjustment by multiple linear regression. In asymptomatic hyperparathyroidism, A986A genotype resulted in a statistically significant higher level of intact PTH, alkaline phosphatase and procollagen amino-terminal propeptide; but only serum calcium remained as an independent predictor of serum intact PTH levels after a multiple linear regression. Bone mineral densitometry between genotypes did not show statistically significant differences. A986S polymorphism of CaSR is an independent predictor of PTH level in normocalcemic hyperparathyroidism patients, but not in asymptomatic hyperparathyroidism. More studies are needed to evaluate the effect of other polymorphisms in normocalcemic and asymptomatic hyperparathyroidism. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26332755     DOI: 10.1055/s-0035-1559723

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  3 in total

Review 1.  Diseases associated with calcium-sensing receptor.

Authors:  C Vahe; K Benomar; S Espiard; L Coppin; A Jannin; M F Odou; M C Vantyghem
Journal:  Orphanet J Rare Dis       Date:  2017-01-25       Impact factor: 4.123

2.  Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.

Authors:  Marian Schini; Richard M Jacques; Eleanor Oakes; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

3.  Comparisons Between Normocalcemic Primary Hyperparathyroidism and Typical Primary Hyperparathyroidism.

Authors:  Hye Ryeon Choi; Sun Hyung Choi; Namki Hong; Yumie Rhee; Jin Kyong Kim; Cho Rok Lee; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2022-04-04       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.